Roche hails another PhIII win on Tecentriq combo, reports promising kidney cancer data
Roche is pedaling hard from behind in the race for PD-1/L1 market supremacy, announcing news at market close Monday that it’s wrapped up yet another promising Phase III combo study using Tecentriq.
With heavyweights like Merck and Bristol-Myers Squibb leading the market, Roche $RHHBY and its subsidiary Genentech are stepping up their game. The latest Phase III study tested Tecentriq with Avastin against advanced or metastatic renal cell carcinoma or kidney cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.